A new study has found that older adults and women taking the weight-loss drug semaglutide may lose more muscle than others, ...

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company's senior executives for ...

GLP-1 receptor agonists semaglutide and tirzepatide are associated with reduced risks of dementia, stroke, and mortality in adults with type 2 diabetes and obesity, new data show.

Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...

A new study suggests that drugs like Ozempic and Mounjaro may reduce dementia risk. Researchers at the University of Galway found a 45% lower risk in patients taking these medications. The drugs may ...

With their lengthening laundry list of health benefits, drugs like Ozempic are showing promise for people who struggle with addiction.

People who took semaglutide over a slower, more flexible schedule were significantly less likely to experience nausea and to ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

In a new study, one nutrient made a difference in muscle loss for people losing weight on drugs like Ozempic. Here's what to eat to preserve your muscle on the meds.

Novo Nordisk A/S (NYSE: NVO) is one of the high-margin pharma stocks to buy now. Berenberg has reaffirmed its Hold rating on ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

Longer treatment duration, using semaglutide, higher percentage body fat, and nondiabetic status may be associated with better weight reduction.